S
tillbirth is a major issue worldwide with an estimated 3.2 million occurring each year. In the United Kingdom, there are around 4000 stillbirths every year, and 1 in every 200 births ends in a stillbirth. 1 In two thirds of cases, the cause is attributed to placental complications, with genetic abnormalities estimated to be between 6% and 13% on karyotyping. The remaining cases despite a detailed autopsy remain unexplained, and this is now the most common single contributor to perinatal mortality. 1 It is enormously distressing to the families involved, and there is significant unmet clinical need in terms of primary and secondary prevention.
Sequence variants in the genes encoding cardiac ion channels or associated regulatory proteins underlie varying inherited arrhythmic syndromes that may lead to arrhythmias and sudden cardiac death (SCD). In patients under 35 years of age, population studies suggest an incidence of cardiac arrest secondary to primary cardiac arrhythmia of 0.4/100 000 person-years. 2 Long-QT (LQT) syndrome, characterized by prolongation of the QT interval and T-wave morphological changes on the ECG, has an estimated population prevalence of 1:2000, 3 the molecular basis of which was initially attributed to mutations in 3 predominant cardiac ion channel genes, although subsequently numerous other genes have been implicated. 4 Given the well-recognized and severe phenotype of infantile long-QT syndrome, the condition has long been implicated in the cause of sudden infant death syndrome (SIDS), and since the initial description, 5 sequence variants in the 3 major long-QT-associated genes have been identified in 10% of such cohorts. 6 This finding suggests that such genetic variants may also be associated with unexplained fetal demise, a hypothesis confirmed by the recent finding that 4% of such cases were associated with mutations in KCNQ1, KCNH2, and SCN5A. 7 With advances in technology, high-quality DNA can be extracted from postmortem tissue, allowing targeted sequencing for mutations that may be associated with a risk of stillbirth. 8 In this study, we used next-generation sequencing to investigate an enlarged panel of 35 candidate genes associated with ion channel disorders and SCD in unexplained stillbirths.
METHODS
The data, analytic methods, and study materials will be available to other researchers for purposes of reproducing the results or replicating the procedure from the corresponding authors.
Participants
We prospectively collected fresh tissue (heart, muscle, kidney) from unexplained stillbirths (≥22 weeks) where no definite cause of death could be identified after a full autopsy, from 4 National Health Service hospitals (University College London Hospital, Great Ormond Street Hospital, Southampton University Hospital, and Sheffield Children's Hospital) between 2007 and 2013, after informed parental consent. In addition, we also included previously archived freshly frozen tissue from a similar cohort from Sheffield Children's Hospital. The Central London Research Ethics Committee 2 approved the study (10/H0713/26).
An experienced perinatal pathologist (N.J.S.) reclassified the unexplained stillbirth cases into 3 groups using a summary of the autopsy report: (1) fully unexplained intrauterine death (IUD), (2) unexplained IUD with placental lesions that have been associated with an increased risk of stillbirth, and (3) partly explained IUD (Table I in the Data Supplement) .
DNA Extraction and Sequencing
We extracted DNA from freshly frozen tissue, primarily muscle (Wizard Genomic DNA Purification Kit; Promega Corporation, Madison), 6 and sequenced a custom panel of 35 genes, including 12 inherited long-QT and short-QT syndrome genes (LQT1-LQT12), and 23 additional candidate genes derived from genome-wide association studies of QT interval, 4,9-11 and genetic studies of catecholaminergic polymorphic ventricular tachycardia, 12 SCD, 13 and developmental disorders (Table II in the Data Supplement). 14 The custom panel was designed using SureDesign (Agilent Technologies, United Kingdom) and included all exons and known transcripts for each gene. An additional 5 kb upstream of exon 1 and downstream of the last exon was also sequenced for the LQT1-LQT9 genes. The MiSeq Multiplexed Sequencing Platform (Illumina Inc) was used for sequencing (Table II in the Data Supplement). All samples followed the same pipeline for sequencing, variant calling, and annotation, and further details are provided in the Data Supplement.
Clinical Perspective
Despite detailed autopsy, a definite cause of death cannot be established in most stillbirth cases. Disruption to sodium and potassium channels in heart cells because of genetic alterations (variants) is known to cause sudden cardiac arrhythmia and deaths in children and adults. In this study, we used next-generation sequencing to examine an extended panel of genes known to be associated with ion channel disorders and sudden cardiac death on postmortem tissues from stillbirth cases. We observed 1 case with a rare genetic variation in a potassium channel, and further experiments indicated that it may change the function of the channel. Several variants of unknown functional significance that may cause cardiac arrhythmia were observed in 5.7% of the stillbirth cases. Our study suggests that a small proportion of stillbirth cases could be because of gene variants causing a fatal cardiac arrhythmia in the womb.
Variant Filtering and Annotation
To identify variants most likely to be functionally damaging, we used the algorithm indicated in Figure 1 . In brief, all synonymous (not protein altering) variants were removed and a list of nonsynonymous variants was assembled. Conservation scores were used to refine the list of variants (GERP++ scores of ≥2), and we annotated the variants using ANNOVAR software, which incorporates SIFT, PolyPhen 2, and Mutation Taster prediction algorithms. 15 We brought forward all nonsynonymous variants which were conserved (GERP++ score of >2). Next, the frequency of the variants was checked in the Exome Aggregation Consortium database, and Exome Sequencing Project and 1000G databases, and variants with frequencies >1% across all ethnicities were removed. 16 Finally, a literature search was undertaken to establish if genetic variants were previously associated with long QT or a related phenotype, and if there was any prior in vitro testing to assess pathogenicity of the variant. We did not have access to parental DNA to assess inheritance of variants, so variants were subsequently categorized into 2 broad categories: (1) putative pathogenic or (2) variant of uncertain significance. 17 A variant was considered as putative pathogenic if it was novel or rare (seen in <0.1% among unrelated and ethnically similar matched controls) and if there was an abnormal electrophysiological phenotype by in vitro functional testing. A variant of uncertain significance was a novel or rare variant with no functional data. Variants in the TTN gene were excluded from this analysis because of the extensive number of variants observed in this gene.
Control Samples
Five hundred sixty-three samples from the 1000 Genomes project 18 were selected as a control sample for burden testing (further information is provided in the Data Supplement). The samples were randomly selected to reflect the same ethnic super code profile as the stillbirth samples, 69.6% European, 3.3% East Asian, and 1.4% African with the remaining 25.7% being randomly selected from the remaining samples in the 1000 Genomes project. As a sensitivity analysis, we also selected a sample from 1000 genomes which comprised only European individuals (n=385).
Burden Testing
Burden tests were performed, for each gene, using Fisher exact test, to compare the proportion of individuals carrying at least 1 rare (allele frequency ≤0.1%) nonsynonymous variant with potential functional consequence, among cases versus controls. Two analyses were done: all ancestry and European only. A Bonferroni-corrected P value (P<0.004; ie, 0.05/13) threshold was used to indicate a significant association for enrichment of rare predicted damaging variants in a gene among stillbirth cases. Only 13 of 35 genes had rare predicted damaging variants in either cases or controls; thus, 13 genes were considered in burden tests.
Power Calculation for Gene-Based Tests
Power calculations for the gene-based Fisher tests were performed using SEQPower software 19 applied to the data for the 13 genes tested at minor allele frequency <0.1% available from the Exome Variant Server reference site frequency spectrum data. The LOGIT model using Fisher genebased test method was used according to the all ancestry sample size of 71 cases and 563 controls. The following assumptions were used: deleterious variants defined as an SIFT score of ≤0.05, disease prevalence set as 1 of 600, and OR range set as 1.2 to 3.
Functional Testing of Novel Variants
We selected a variant in KCNJ2 (p. R40Q) for functional analyses by patch-clamp electrophysiological recording to assess its pathogenicity, after reconfirmation of the variant by Sanger sequencing. The KCNJ2 channel (kindly supplied courtesy of Yoshihiro Kubo, National Institute for Physiological Sciences, Japan) was subcloned into pcDNA3.1(+), and site-directed mutagenesis was used to introduce the variant. 20 The wildtype channel, Thr353Ala variant, Arg40Gln variant, or empty vector pcDNA3.1(+) was transiently transfected into CHO-K1 cells 48 hours before patch-clamp analysis. Whole-cell patch clamp was used as previously described to establish if the variant affected the functional properties of the current produced by KCNJ2. 21 Data are presented as mean and SEM, and comparisons were made using a t test, and P values <0.05 were considered significant.
RESULTS
We extracted the DNA from a total of 242 cases, which were of high quality in 70, and these were successfully sequenced. The demographic characteristics of the stillbirth cases are provided in Table 1 . The mean gestational age was 33.95 weeks at death (SD±6.18), and there was no significant difference between male and female age, 33.6±6.617 versus 34.5±5.734 (P=0.55). A total of 57% of the cases were male, and 67% were of European ancestry, 4.3% were Asian ancestry, 2.6% were African, and ancestry was unknown in 25.7%. Additional details of the clinical characteristics and categorization of the 70 stillbirth cases are provided in Table I in the Data Supplement.
The 70 cases included in this study were sequenced on average to a mean coverage depth of 132× per sample. Ninety-seven percent of the target was covered at least 15× to ensure accurate calling of heterozygous variants. After QC, our sequencing analysis identified 1964 genetic variants across the 70 stillbirth cases. Of these, 683 were exonic, and 327 were nonsynonymous variants. There were no deletions, insertions, nonsense variants observed in any candidate gene. Splice-site variants were observed in TTN and TRPM7. Forty-three conserved and predicted potentially damaging nonsynonymous variants were found in 41 of 70 cases (58.7%). Eighteen of these variants were in established LQT genes: one novel in CACNA1C and 17 rare (AKAP9, ANK2, CACNA1C, KCNE1, KCNE2, KCNJ2, and SCN5A). We did not identify any predicted damaging variants in KCNQ1 (LQT1) or KCNH2 (LQT2). Twenty-five predicted damaging variants in non-LQT genes were observed, 6 of these were novel, and 19 were rare (Table III in the  Data Supplement) .
One case had a putative pathogenic variant in an LQT gene, KCNJ2 (LQT7; Table 2 ). Case 27 was an IUD with placental-fetal thrombotic vasculopathy; it was heterozygous for a very rare (0.0015%) variant in KCNJ2 (p. Arg40Gln; Figure 2A through 2C) . We performed in vitro electrophysiological studies using whole-cell patch clamping to determine if this variant affected channel function. Another novel nonsynonymous variant (p. Thr353Ala) found in an explained fetal demise sample was also tested (Figure 2 ). CHO-K1 cells transiently transfected with empty vector control (pcDNA3.1) did not possess a large inward current, whereas those transfected with KCNJ2-WT or KCNJ2-T353A produced large inward currents with similar levels of current density ( Figure 2D ). In contrast, the homozygous expression of KCNJ2-R40Q produced currents with significantly reduced current density (P<0.05) in comparison to KCNJ2-WT ( Figure 2E ). In detail, the R40Q mutation, when expressed in homozygous fashion, leads to an approximate 70% reduction in the level of inward current (measured at −150 mV; Figure 2F ). The reduction in current density for the Arg40Gln variant indicated that this variant is likely to result in compromised channel function.
Low-frequency variants were observed in 3 LQT genes: SCN5A (LQT3), KCNE1 (LQT5), and KCNE2 (LQT6) with reported functional data ( Table 2) . Case 61, an unexplained IUD who had a normal autopsy and placental histology, was heterozygous for 2 LQT genetic variants: (p. Asp85Ala: KCNE1) and (p. Thr8Ala: KCNE2). The p. Thr8Ala variant in KCNE2 is low frequency (allelic frequency 0.4%), is located at the N terminus, and has been reported in association with antibiotic-induced arrhythmia and SIDS. 22, 23 Functional studies have shown that this variant when expressed with the hERG channel has a 15% reduction in current densities compared with wild type and has an increased sensitivity to treatment with sulfamethoxazole and trimethoprim (agents associated with QT prolongation). 22 The Asp85Asn variant in KCNE1 has a minor allele frequency of 0.038. This variant has been reported to be associated with drug-induced LQTS, an odds ratio of 9.0. 24 Functional studies indicate that this variant, when coexpressed with either KCNQ1 or KCNH2, is associated with decreased current density (compared with wild-type KCNE1). 25 Case 67 was heterozygous for a relatively rare variant, p. Gly615Glu (0.039%) in SCN5A. This variant is located in the DI/DII linker region of the channel protein and is associated with shorter recovery times from inactivation in a Xenopus oocyte expression system. A similar change in channel function has been observed for other SCN5A variants which have been reported in association with SIDS. 26 Case 5, an unexplained IUD with placental lesions, was heterozygous for the variant p. Arg481Trp in SCN5A. This variant has previously been reported as increasing the risk of LQT, SCD, torsades de pointes, or acquired LQT. [26] [27] [28] It has previously been reported in an African case and has been shown to affect activation, inactivation, or recovery time of the channel depending on the SCN5A splice variant tested. 28 
Novel Variants of Uncertain Significance
Seven novel variants of uncertain significance were observed in the stillbirth cases (Table IV in the Data Supplement). Case 6 was heterozygous for p. Pro1845Leu in CACNA1C (LQT8), a variant located within the C-terminal topological domain (amino acid residues 1525-2221). Five novel variants were observed in 5 QT genome-wide association study candidate genes: TRPM7, SCN10A, CREBBP, SRL, and BAZ2B. Case 43 was heterozygous for a p. Trp860Met variant in TRPM7; this variant is located in the second transmembrane domain of the ion channel. Case 52 was heterozygous for p. Trp1570Ala variant in SCN10A. We observed 5 cases that were heterozygous for p. Gln2251Lys in CREBBP. The variant substitutes a glutamine residue from an identified poly-Q region (2199-2216). Case 69 was heterozygous for a BAZ2B variant at p. Asp636Asn. Case 36 was heterozygous for p. Glu22Asp in the SRL gene. We also observed 1 case (case 46) that was heterozygous for p. His513Tyr in RYR2, a candidate gene for catecholaminergic polymorphic ventricular tachycardia; however, this lies outside the known functional domains where the vast majority of disease-associated mutations cluster.
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Rare Variants of Uncertain Significance
There were several cases with rare variants of uncertain significance that had been previously reported as associated with sudden unexplained death, arrhythmias, or torsades de pointes. These included a rare RYR2 vari- ant (p. Val2113Met) found from sequencing of a sudden unexplained death population. 29 The p. Asn687Ser variant in ANK2 has previously been reported in an individual with TdP. 30 Finally, a p. R1268Q variant in SCN10A, this has previously been reported in an individual with Brugada syndrome, and functional testing has indicated an 84% reduction in sodium current when expressed with wild-type SCN5A compared with wild-type SCN10A.
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Testing for Enrichment of Rare Functional Variants
A significant number of rare functional variants were observed in public sequence databases; therefore, we performed a burden test to detect genes with a significant enrichment in rare predicted damaging variants (minor allele frequency<0.1%) in stillbirth cases verses 563 randomly selected controls (Methods). We did not observe significant evidence of enrichment of rare predicted damaging variants in stillbirth cases within any of the 13 tested genes (Table 3) . Similarly, there was no evidence of enrichment in samples of European ancestry only (Table V in the Data Supplement). A power calculation set at the 5% α significance level for a 1-sided test indicated the average power as 51% across the 13 genes.
DISCUSSION
Here, we report the data from an extensive molecular autopsy in unexplained stillbirth involving 35 genes associated with ventricular arrhythmia and SCD, using next-generation sequencing. We found putative pathogenic variants that might be associated with fetal demise in 4 (5.7%) cases. Three of these variants had reported functional data-KCNE1 and KCNE2 (1 case) and SCN5A (2 cases), and one was a very rare variant in KCNJ2 (p. Arg40Gln) that affected the function of the channel. Predicted damaging variants were found in 37 (53.0%) of the remaining 66 cases; these were of uncertain significance in this setting.
In contrast to a previous study that investigated the role of LQT variants in intrauterine fetal death, 7 we found no predicted damaging variants in LQT1 and LQT2 genes KCNQ1 or KCNH2. We observed 3 SCN5A (minor allele frequency<1%) variants in our population with functional data available. This observation is in agreement with an earlier hypothesis of an increased prevalence of sodium channel variants in SIDS compared with potassium channel variants in stillbirth. 32 Interestingly, mutations in KCNJ2 that do not result in Andersen-Tawil syndrome but affect cardiac function have recently been identified. 33 These mutations tend to not result in a complete loss of channel function, in a similar manner to the Arg40Gln variant we have identified, which may explain why these patients have an isolated cardiac phenotype and lack extra cardiac dysmorphic features. 33 How the predicted damaging variants identified in this study may contribute to the mechanism of intrauterine fetal demise is difficult to determine. We do not have proof of mechanism of death, or recording of fetal arrhythmias, nor do we have evidence from other studies of other patients with the same variants demonstrating convincing pathogenicity. In future studies, pathogenicity could be examined in cardiomyocytes derived from induced pluripotent stem cells that carry these variants. Large-scale population-based genomewide association study would also be required to examine potential causal relationships.
Nevertheless, it is possible that a multiple hit hypothesis similar to that proposed in SIDS (combination of pathogenic variants and of functional polymorphisms triggering lethal cardiac events when combined with specific environmental factors during a critical developmental phase) may also be applicable to unexplained stillbirths. For example, environmental factors may include nonlethal placental pathologies, or milder degrees of intrauterine infection, that might trigger a lethal fetal cardiac arrhythmia. This hypothesis is supported by recent observations in kcnj8 knockout mice models in which induced vasospasm by ergometrine, lipopolysaccharide-induced sepsis, or cytomegalovirus triggered sudden death. 34 Furthermore, fetal arrhythmias related to ion channelopathies have been reported in settings where there is routine fetal screening. 35 Of potential interest is the observation of novel variants in putative candidate genes derived from genomewide association study of the QT interval. TRPM7 is a ubiquitously expressed nonselective ion channel kinase which plays a key role in embryonic cardiogenesis and establishing cardiac automaticity. Alongside its role in heart development, the channel regulates magnesium homeostasis, and a Thr1482Ile variant has been found (9) 0.047 *The controls were randomly selected from the 1000G data set to match the self-reported ethnicity of the stillbirth cases (methods); % cases or controls is provided in parentheses; the TTN gene was not included in this analysis because of the extensive number of variants.
to be associated with Guamanian neurodegenerative disorder. 36 Sequencing of TRPM7 in LQT patients indicated variants in this gene as good candidates for inherited LQT. We observed 1 stillbirth case that was heterozygous for a novel variant in TRPM7 (p. Thr860Met), and several other cases were heterozygous for low-frequency variants in this gene. Of note, TRPM7 was the only gene which had suggestive evidence of enrichment (before Bonferroni correction) in the burden testing. We also observed a splice-site variant in this gene in 1 stillbirth case (Table III in the Data Supplement) . Functional studies of TRPM7 and its relationship to stillbirth may warrant more detailed analyses.
A second candidate gene of interest is SCN10A. SCN10A encodes a voltage-gated sodium channel α subunit Nav1.8 which consists of 4 homologous domains each with 6 transmembrane spanning regions of which one is a voltage sensor. Nav1.8 can also associate with ≥1 β units. Mutations in SCN10A have been associated with Brugada syndrome and can modulate SCN5A expression (LQT3).
1 Patients with BrS who had SCN10A mutations were more symptomatic and displayed significantly longer PR and QRS intervals compared with SCN10A-negative BrS probands. 2 However, more recent data have put these findings into doubt. Burden testing of SCN10A showed a lack of significant enrichment for rare coding variation in cases of BrS in a population of European ancestry. 37 Likewise our Burden test indicated no significant enrichment of rare functional variants within SCN10A among stillbirth cases.
The CREBBP gene encodes a histone acetyl transferase and coactivator. Interestingly, in our study, we identified 5 cases with a novel p. Gln2251Lys nonsynonymous variant. Variants in CREBBP have been associated with acute lymphoblastic leukemia and Rubinstein-Taybi syndrome; Rubinstein-Taybi syndrome patients have a history of cardiac abnormalities with previous work revealing a link between the syndrome, congenital heart defects, and conductive abnormalities. The novel variant we identified lies 100 residues upstream of the nuclear receptor coactivator binding domain. Five separate cases contained variants in BAZ2B which encodes bromodomain adjacent to zinc finger domain 2B, an epigenetic regulator which has been associated with SCD susceptibility. 38 Case 36 was heterozygous for a novel SRL variant, a gene physiologically involved in calcium storage in muscle tissue. 39 One case possessed a rare SMARCAD1 variant; this DNA helicase is required for DNA repair and heterochromatin organization. Another case was heterozygous for a rare variant in MKL2, a gene previously noted as required for myogenic differentiation. 40 This study is not without limitations. First, our sample size is small owing to the difficulties in postmortem research consenting, and the phenotype is relatively broad. Some of the stillbirth cases in this cohort could be considered partially explained, for example, the case with presence of placental-fetal thrombotic vasculopathy. We did not exclude such cases because the clinical significance of such focal placental changes remains uncertain and it is possible that cardiac ion channelopathies might increase the risk of death in a compromised fetus. Second, we did not have any data of fetal cardiac arrhythmias in the recruited cases. Third, we used data from the 1000 genomes study as control data for burden testing. As variants across cases and controls were not called together, it is possible that variants in cases are novel because of this issue. Fourth, the gene-based testing was underpowered (using the best-case scenario of causality assumptions) with only ≈51% power achievable from our sample sizes. Finally, parental DNA was not available to assess if the variants were de novo mutations or were inherited, nor did we have details on family history of cardiac ion channelopathies. Declining autopsy rates, and challenges associated with consenting of bereaved parents, are major hurdles to research in this area.
Given that cardiac ion channelopathies may be a preventable cause of sudden death (for example, the mortality from LQT can be reduced significantly with appropriate therapy), the novel and rare variants we report may be of clinical interest, if future studies are able to establish clearer mechanistic and inheritance pathways.
In summary, these preliminary data indicate that putative pathogenic variants resulting in cardiac channelopathies may exist in some cases of otherwise unexplained stillbirths. It is possible that these variants may have had a role in the fetal demise. Cartwright is supported by a grant (FS/13/58/30648) from the British Heart Foundation. The sponsor or the funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
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